Quantum BioPharma Ltd. Financial Report: February 2025 Insights & Press Release

Key Information Extracted from the Financial Report (Form 6-K)

1. Registrant Information:

• Company Name: Quantum BioPharma Ltd.
• Address: 55 University Ave., Suite 1003, Toronto, Ontario M5J2H7, Canada.
• Commission File Number: 001-39152.

2. Filing Type:

• This document is a Form 6-K which is used by foreign private issuers to report material events.

3. Reporting Period:

• The report pertains to the month of February 2025.

4. Annual Report Filing:

• The registrant indicates it files annual reports under Form 20-F.

5. Press Release:

• On February 10, 2025, Quantum BioPharma Ltd. issued a press release, referenced as Exhibit 99.1, which is attached to the report.

6. Signature:

• The report was signed by Donal Carroll, who is the Chief Financial Officer of Quantum BioPharma Ltd., on February 10, 2025.

7. Exhibit Index:

• Exhibit 99.1: Press Release dated February 10, 2025.

Insights:

• The filing indicates that Quantum BioPharma Ltd. is actively reporting to the SEC and maintains compliance with regulatory requirements for foreign issuers.
• The issuance of a press release suggests that the company may have communicated important information to its stakeholders, which could have implications for its financial performance or market perception.
• The filing under Form 20-F indicates that the company is engaged in a level of transparency that is typically expected from larger, more established entities in the market.

This summary encapsulates the core details of the report and highlights the company's compliance and communication practices.